Novartis’ Tobi Podhaler (tobramycin) has been recommended for treating chronic pulmonary infection caused by Pseudomonas aeruginosa in people with cystic fibrosis only if a nebulised version is considered appropriate and is supplied under an agreed patient access scheme (PAS).
Forest Laboratories UK’s Colobreathe (colistimethate sodium) has also been recommended for the same indication if patients would benefit clinically from continued use of the treatment but do not tolerate its nebulised form and Podhaler therapy would otherwise be considered. The treatment must also be supplied under the terms of an agreed PAS.
Professor Carole Longson, Health Technology Evaluation Centre Director at NICE, said the Institute was “pleased” to recommend the treatments for one of the primary causes of death in people with CF.
Cystic fibrosis is one of the UK’s most common life-threatening inherited diseases. It currently affects around 8,000 people.